trα

TR-107 (Anticancer agent 230) is a selective and potent activator of the mitochondrial protease ClpP that inhibits tumor growth in the MDA-MB-231 xenograft model.

TR-14035 (MDK-1191) is a dual antagonist of α4β7 α4β1 integrins (IC50s: 7 87nM).

TR antagonist 1 is a highly potent thyroid hormone receptor (TR) antagonist (IC50 of 36 and 22 nM for TRα and TRβ, respectively) that can be used to study diseases caused by endocrine abnormalities.

Tr-PEG8-OH, a non-cleavable 8-unit PEG ADC linker, is utilized in the synthesis of antibody-drug conjugates (ADCs).

Nucleoside Derivatives –Morpholino nucleosides

Tr-PEG2-OH is a PEG-based PROTAC linker used in PROTAC synthesis[1] and a non-cleavable 2-unit PEG ADC linker for antibody-drug conjugate (ADC) synthesis[2].

Methoxy-Tr-NH-PEG7 is a PEG-based linker for PROTACs, joining two essential ligands crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Ganoderic acid TR is a broad-spectrum inhibitor of influenza neuraminidases (NAs), particularly H1N1 and H5N1 neuraminidases, with IC50 values of 4.6 and 10.9 μM, respectively.

Tr-PEG6-OH is a 6-unit polyethylene glycol (PEG) linker, which is non-cleavable and extensively employed in the synthesis of antibody-drug conjugates (ADCs).

Tr-PEG5-OH is a non-cleavable 5-unit PEG ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs).

Tr-PEG4-OH is a non-cleavable tetraethylene glycol ADC linker used in ADC synthesis for the conjugation of antibodies and drugs.

Tr-PEG3-OH, a non-cleavable three-unit PEG ADC linker, is used in the synthesis of antibody-drug conjugates (ADCs).

Anti-Mouse TNFR2 Antibody is an IgG inhibitor derived from Armenian Hamster, specifically targeting mouse TNFR2.

TR4161 is a prostaglandin bronchodilator of low tracheobronchial irritancy.

TRβ agonist 3 (Compound 3) is a potent TRβ agonist and a potential TRβ-selective thyromimetic. In vitro studies show that TRβ agonist 3 reduces lipid accumulation in HepG2 cells and promotes lipolysis [1].

TRβ agonist 2 (Compound 1) is a highly potent TRβ agonist that effectively reduces lipid accumulation in HepG2 cells and promotes lipolysis, offering comparable effects. With its promising attributes, TRβ agonist 2 emerges as a potential thyromimetic selectively targeting TRβ [1].

TRβ Agonist 1, a selective and mutation-sensitive thyroid hormone receptor β (TRβ) agonist, demonstrates an EC50 value of 21 nM. It is useful in the research of dyslipidemia, nonalcoholic steatohepatitis (NASH), and resistance to thyroid hormone (RTH) [1].

Liothyronine (Tresitope) is an active form of thyroid hormone, binding to β1 thyroid hormone receptor (TRβ1), and activates its activity.

Liothyronine Sodium is the sodium salt form of liothyronine, a synthetic form of the levorotatory isomer of the naturally occurring thyroid hormone triiodothyronine (T3). Liothyronine sodium (3,3',5-Triiodo-L-thyronine sodium) binds to nuclear thyroid receptors which then bind to thyroid hormone response elements of target genes. As a result, liothyronine sodium induces gene expression that is required for normal growth and development. Liothyronine sodium is more potent and has a more rapid action than thyroxine (T4).

Eprotirome (KB2115), a synthetic thyroid hormone mimetic, is a thyroid hormone receptor agonist.

Sobetirome (IACS-010759) is a selective agonist of thyroid hormone receptor β (TRβ) and binds selectively to TRβ-1 (EC50: 0.16 μM).

GC 14 is a selective thyroid hormone receptor antagonist with IC50 values of 200 nM for hTRα and 35 nM for hTRβ.

Liothyronine sodium hydrate (Triiodothyronine sodium hydrate) is a TRα and TRβ agonist and a thyroxine analog with anticancer and antitumor activities. It can be used to study hypothyroidism, stroke and cognitive dysfunction.

CO23 is a blood-brain barrier penetrant and selective TRα agonist and can be used in studies about the regulation of growth and development.